acute myeloid leukemia Archives | Be Korea-savvy
Helsinn to Co-support a Satellite Symposium on Current and Emerging Treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

Helsinn to Co-support a Satellite Symposium on Current and Emerging Treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

Lugano, Switzerland, Jun. 12 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it will co-support a satellite symposium around current and emerging treatment options for Acute Myeloid Leukemia (AML) at the 24th European Hematology Association (EHA) Congress. The symposium, titled “Current and Emerging Treatment Options in AML: [...]

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the Design of the Phase III PRIMULA Study of Pracinostat in Combination with Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the Design of the Phase III PRIMULA Study of Pracinostat in Combination with Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

Lugano, Switzerland, May 30 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announce that the PRIMULA study design will be presented at [...]

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

SAN DIEGO, May 8 (Korea Bizwire) — Invivoscribe Technologies, Inc. announced today that they have submitted to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) product registrations based on the ongoing Phase III CL-0301 ADMIRAL study evaluating gilteritinib for the treatment of FLT3 mutation-positive (FLT3mut+) relapsed or refractory [...]